Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Mira Pharmaceuticals Inc (MIRA)

Mira Pharmaceuticals Inc (MIRA)
0.8500 x 19 0.8799 x 25
Post-market by (Cboe BZX)
0.8344 -0.0656 (-7.29%) 04/04/25 [NASDAQ]
0.8500 x 19 0.8799 x 25
Post-market 0.8799 +0.0455 (+5.45%) 18:08 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8065
Day High
0.9400
Open 0.9400
Previous Close 0.9000 0.9000
Volume 135,700 135,700
Avg Vol 362,890 362,890
Stochastic %K 6.22% 6.22%
Weighted Alpha -81.00 -81.00
5-Day Change -0.2256 (-21.28%) -0.2256 (-21.28%)
52-Week Range 0.5100 - 5.0100 0.5100 - 5.0100
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,133
  • Shares Outstanding, K 16,814
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,850 K
  • EBIT $ -6 M
  • EBITDA $ -8 M
  • 60-Month Beta 2.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.14
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.52
  • Most Recent Earnings $-0.15 on 03/28/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.15
  • Number of Estimates 1
  • High Estimate -0.15
  • Low Estimate -0.15
  • Prior Year -0.12
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8065 +3.46%
on 04/04/25
Period Open: 0.9300
1.3280 -37.17%
on 03/13/25
-0.0956 (-10.28%)
since 03/04/25
3-Month
0.8000 +4.30%
on 03/04/25
Period Open: 1.2600
1.5000 -44.37%
on 01/07/25
-0.4256 (-33.78%)
since 01/03/25
52-Week
0.5100 +63.61%
on 07/03/24
Period Open: 1.0200
5.0100 -83.35%
on 07/22/24
-0.1856 (-18.20%)
since 04/04/24

Most Recent Stories

More News
MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIAMI, FLORIDA / ACCESS Newswire / April 1, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric...

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

Strategic acquisition expands MIRA's pipeline with SKNY-1, a next-generation oral therapeutic targeting the two leading causes of preventable death-obesity and smoking.

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIAMI, FL / ACCESS Newswire / March 13, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders,...

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

MIAMI, FL / ACCESS Newswire / March 4, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment

MIRA Pharmaceuticals submitted an Investigational New Drug application to the FDA for Ketamir-2, its novel oral ketamine analog for neuropathic pain, marking a significant milestone in its mi

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIAMI, FLORIDA / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric...

MIRA : 0.8344 (-7.29%)
MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

Strong Safety Profile Validated Across Studies, Setting the Stage for Clinical Trials in Neuropathic Pain

MIRA : 0.8344 (-7.29%)
MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

Backed by a Strong Balance Sheet, MIRA Accelerates Toward Becoming a Clinical-Stage Company and Advancing Breakthroughs in Pain and Depression Treatment

MIRA : 0.8344 (-7.29%)
Hope for Chemo Patients: New Pre-Clinical Study Shows Mira Pharmaceuticals Ketamir-2 Beats Competitors' Chemo Pain Reduction by Over 60%

MIRA Pharmaceuticals' novel oral ketamine analog, Ketamir-2, has shown superior efficacy in reducing neuropathic pain compared to leading treatments like Gabapentin and Pregabalin, with the p

MIRA : 0.8344 (-7.29%)
Ketamir-2 from MIRA Pharmaceuticals Raises the Bar in Pain Management, Outshining FDA-Approved Treatments

MIRA Pharmaceuticals' Ketamir-2 shows promise in treating neuropathic pain as a safer and more effective alternative to current medications, with potential applications in mental health as we

MIRA : 0.8344 (-7.29%)

Business Summary

MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline...

See More

Key Turning Points

3rd Resistance Point 1.0476
2nd Resistance Point 0.9938
1st Resistance Point 0.9141
Last Price 0.8344
1st Support Level 0.7806
2nd Support Level 0.7268
3rd Support Level 0.6471

See More

52-Week High 5.0100
Fibonacci 61.8% 3.2910
Fibonacci 50% 2.7600
Fibonacci 38.2% 2.2290
Last Price 0.8344
52-Week Low 0.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades